These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22033942)

  • 1. TET2: epigenetic safeguard for HSC.
    Ko M; Rao A
    Blood; 2011 Oct; 118(17):4501-3. PubMed ID: 22033942
    [No Abstract]   [Full Text] [Related]  

  • 2. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
    Schaub FX; Lehmann T; Looser R; Hao-Shen H; Tichelli A; Skoda RC
    Blood; 2011 Feb; 117(6):2075-6. PubMed ID: 21310937
    [No Abstract]   [Full Text] [Related]  

  • 3. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
    Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
    Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells.
    Zhao Z; Chen S; Zhu X; Pan F; Li R; Zhou Y; Yuan W; Ni H; Yang FC; Xu M
    Leukemia; 2016 Aug; 30(8):1784-1788. PubMed ID: 27003514
    [No Abstract]   [Full Text] [Related]  

  • 5. [In cauda venenum or the importance of TET(2)].
    Mercher T; Quivoron C; Couronné L; Vainchenker W; Bastard C; Bernard OA
    Med Sci (Paris); 2011 Dec; 27(12):1064-6. PubMed ID: 22192742
    [No Abstract]   [Full Text] [Related]  

  • 6. TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2
    Li R; Zhou Y; Cao Z; Liu L; Wang J; Chen Z; Xing W; Chen S; Bai J; Yuan W; Cheng T; Xu M; Yang FC; Zhao Z
    Stem Cell Reports; 2018 Jan; 10(1):166-179. PubMed ID: 29290626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples.
    Pignataro DS; Abdel-Wahab O
    Leuk Res; 2012 Jan; 36(1):25-6. PubMed ID: 21917313
    [No Abstract]   [Full Text] [Related]  

  • 8. [TET2 as a gatekeeper for hematologic malignancies].
    Muto H; Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
    Li R; Xu MJ; Yang FC; Zhou Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
    Tefferi A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Patnaik MM; Hanson CA; Pardanani A; Gilliland DG; Levine RL
    Leukemia; 2009 Jul; 23(7):1343-5. PubMed ID: 19295549
    [No Abstract]   [Full Text] [Related]  

  • 12. TET2 loss, a rescue of JAK2V617F HSCs.
    Vainchenker W; Plo I
    Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [TET2 dysregulation in hematologic malignancies].
    Sakata-Yanagimoto M
    Rinsho Ketsueki; 2014 Oct; 55(10):1893-902. PubMed ID: 25297753
    [No Abstract]   [Full Text] [Related]  

  • 14. TET2, a tumor suppressor in hematological disorders.
    Mercher T; Quivoron C; Couronné L; Bastard C; Vainchenker W; Bernard OA
    Biochim Biophys Acta; 2012 Apr; 1825(2):173-7. PubMed ID: 22240200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
    Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
    Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functional analysis of TET2 using a knockdown mouse model].
    Shide K; Kameda T; Shimoda K
    Rinsho Ketsueki; 2015 Jun; 56(6):657-65. PubMed ID: 26256876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
    Jardin F; Ruminy P; Parmentier F; Troussard X; Vaida I; Stamatoullas A; Leprêtre S; Penther D; Duval AB; Picquenot JM; Courville P; Capiod JC; Tilly H; Bastard C; Marolleau JP
    Br J Haematol; 2011 May; 153(3):413-6. PubMed ID: 21275969
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aberrant cytosine hydroxymethylation in hematologic malignancies].
    Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2013 May; 54(5):423-30. PubMed ID: 23727679
    [No Abstract]   [Full Text] [Related]  

  • 19. FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.
    La Starza R; Crescenzi B; Nofrini V; Barba G; Matteucci C; Brandimarte L; Pierini V; Testoni N; Musto P; Paolini S; Gianfelici V; Storlazzi CT; Pierini A; Berchicci L; Gorello P; Mecucci C
    Leuk Res; 2012 Jan; 36(1):37-41. PubMed ID: 21920603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TET2 interactors and their links to hematological malignancies.
    Pan F; Weeks O; Yang FC; Xu M
    IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.